Replies to post #213556 on Biotech Values

[xavierprivas]

ganaxolone has shown to have less efficacy than SAGE-547 for epilepsy. The advantage for ganaxolone is the safer toxic profile which allows for long term use.

That is why SAGE-547 is targeted at SRSE the acute form of epilepsy where
long term use is not needed. PPD is another indication where long term use
is not needed if the drug actually works.

Ganaxolone has never been tested in PPD. Captisol might not help much
if the efficacy is poor in the first place, but this is just my opinion, not
based on any scientific evidence. It could work in PPD.

Ecor1 does not hold any SAGE in 2017. Deerfield sold all their SAGE in 2Q17
as their filings showed. I started buying MRNS when I noticed Deerfield buying
into MRNS but I am out of it since last week at a good profit.